Kush Parmar - Nov 2, 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Nov 2, 2021
Transactions value $
$5,000,000
Form type
4
Date filed
11/5/2021, 08:49 AM
Previous filing
Nov 1, 2021
Next filing
Nov 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Conversion of derivative security +319K +96.21% 650K Nov 2, 2021 See Footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +2.37M +365.01% 3.02M Nov 2, 2021 See Footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +564K 564K Nov 2, 2021 See Footnote F1, F3
transaction TRDA Common Stock Conversion of derivative security +255K +8.42% 3.28M Nov 2, 2021 See Footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +318K +56.39% 882K Nov 2, 2021 See Footnote F1, F3
transaction TRDA Common Stock Purchase $5M +250K +28.33% $20.00 1.13M Nov 2, 2021 See Footnote F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Series Seed Preferred Stock Conversion of derivative security $0 -319K -100% $0.00* 0 Nov 2, 2021 Common Stock 319K See Footnote F1, F2
transaction TRDA Series A Preferred Stock Conversion of derivative security $0 -2.37M -100% $0.00* 0 Nov 2, 2021 Common Stock 2.37M See Footnote F1, F2
transaction TRDA Series A Preferred Stock Conversion of derivative security $0 -564K -100% $0.00* 0 Nov 2, 2021 Common Stock 564K See Footnote F1, F3
transaction TRDA Series B Preferred Stock Conversion of derivative security $0 -255K -100% $0.00* 0 Nov 2, 2021 Common Stock 255K See Footnote F1, F2
transaction TRDA Series B Preferred Stock Conversion of derivative security $0 -318K -100% $0.00* 0 Nov 2, 2021 Common Stock 318K See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
F2 Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
F3 Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
F4 On November 2, 2021, Opportunities purchased 250,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.